 |
8 Diseases |  |
17 Trials |
|
17 Trials |  |
2602 News |  |
| «12...13141516171819202122232425 |
- ||||||| Lemtrada (alemtuzumab) / Sanofi
Trial completion: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (clinicaltrials.gov) - Mar 14, 2016
P3, N=1322, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed
- Lemtrada (alemtuzumab) / Sanofi
Clinical: SCALA: A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 15, 2015
P1, N=24, Recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Lemtrada (alemtuzumab) / Sanofi
Biomarker, New trial: Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients (clinicaltrials.gov) - Dec 9, 2015
P=N/A, N=10, Recruiting, Sponsor: Clinique Neuro-Outaouais
- | Lemtrada (alemtuzumab) / Sanofi
Clinical: SCALA: A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2015
P1, N=24, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- Lemtrada (alemtuzumab) / Sanofi
New trial: Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: Hadassah Medical Organization
- ||| Lemtrada (alemtuzumab) / Sanofi
Clinical: EMERALD: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (clinicaltrials.gov) - Jun 16, 2015
P4, N=56, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Lemtrada (alemtuzumab) / Sanofi
Enrollment open: ALAIN01: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (clinicaltrials.gov) - May 28, 2015
P4, N=15, Recruiting, Sponsor: University Hospital Muenster
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Lemtrada (alemtuzumab) / Sanofi
New P4 trial: ALAIN01: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (clinicaltrials.gov) - Apr 17, 2015
P4, N=15, Not yet recruiting, Sponsor: University Hospital Muenster
- || Lemtrada (alemtuzumab) / Sanofi
Enrollment status: TOPAZ: Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (clinicaltrials.gov) - Mar 7, 2015
P4, N=812, Enrolling by invitation, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting Recruiting --> Enrolling by invitation
- Lemtrada (alemtuzumab) / Sanofi
Enrollment closed, Metastases: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 20, 2015
P4, N=8, Active, not recruiting, Sponsor: University of Chicago
Recruiting --> Enrolling by invitation Enrolling by invitation --> Active, not recruiting
- |||| Lemtrada (alemtuzumab) / Sanofi
Enrollment open, Enrollment change: TOPAZ: Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (clinicaltrials.gov) - Jan 12, 2015
P4, N=812, Recruiting, Sponsor: Genzyme, a Sanofi Company
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting | N=1248 --> 812
- |||| Lemtrada (alemtuzumab) / Sanofi
Trial completion: A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif (clinicaltrials.gov) - Jan 8, 2015
P2, N=334, Completed, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting | N=1248 --> 812 Active, not recruiting --> Completed
- ||||| Lemtrada (alemtuzumab) / Sanofi
New P4 trial: TOPAZ: Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (clinicaltrials.gov) - Oct 2, 2014
P4, N=1248, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- |||| Lemtrada (alemtuzumab) / Sanofi
Clinical: EMERALD: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (clinicaltrials.gov) - Sep 28, 2014
P4, N=56, Recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Lemtrada (alemtuzumab) / Sanofi
Clinical: EMERALD: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (clinicaltrials.gov) - Aug 1, 2014
P4, N=56, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- Lemtrada (alemtuzumab) / Sanofi
Enrollment closed: Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects (clinicaltrials.gov) - Mar 7, 2014
P1, N=60, Active, not recruiting, Sponsor: Samuel Forrester Hunter, MD, PhD
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Lemtrada (alemtuzumab) / Sanofi
Enrollment change, Metastases: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 22, 2014
P4, N=8, Enrolling by invitation, Sponsor: University of Chicago
Recruiting --> Active, not recruiting N=10 --> 8
- | Lemtrada (alemtuzumab) / Sanofi
Enrollment closed, MRI, Metastases: iCAMMS-IST: Advanced MRI Measures of Repair in Alemtuzumab Treated Patients (clinicaltrials.gov) - Dec 9, 2013
P3, N=25, Active, not recruiting, Sponsor: University of British Columbia
N=10 --> 8 Enrolling by invitation --> Active, not recruiting
- Trial termination: High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment (clinicaltrials.gov) - Nov 20, 2013
P2, N=1, Terminated, Sponsor: Seah Lim M.D.
Enrolling by invitation --> Active, not recruiting Recruiting --> Terminated; Insufficient accruals; PI leaving site
- Enrollment change: High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment (clinicaltrials.gov) - Nov 20, 2013
P2, N=1, Terminated, Sponsor: Seah Lim M.D.
Recruiting --> Terminated; Insufficient accruals; PI leaving site N=50 --> 1
- | New P4 trial: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin (EUDRACT) - Nov 19, 2013
P4, N=60, Ongoing, Sponsor: Turku University Hospital
- | Lemtrada (alemtuzumab) / Sanofi
Enrollment change, MRI, Metastases: iCAMMS-IST: Advanced MRI Measures of Repair in Alemtuzumab Treated Patients (clinicaltrials.gov) - Jan 15, 2013
P3, N=25, Active, not recruiting, Sponsor: University of British Columbia
N=50 --> 1 N=20 --> 25
- | Lemtrada (alemtuzumab) / Sanofi
New P1/2 trial: CAM-THY: Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2012
P1/2, N=86, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
- New P2 trial: High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment (clinicaltrials.gov) - Sep 3, 2012
P2, N=1, Terminated, Sponsor: Seah Lim M.D.
- Lemtrada (alemtuzumab) / Sanofi
New P1 trial: Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects (clinicaltrials.gov) - Jun 19, 2012
P1, N=60, Active, not recruiting, Sponsor: Samuel Forrester Hunter, MD, PhD
- ||||||| Lemtrada (alemtuzumab) / Sanofi
Trial completion: CARE-MS II: Comparison of Alemtuzumab and Rebif (clinicaltrials.gov) - Jan 29, 2012
P3, N=840, Completed, Sponsor: Genzyme, a Sanofi Company
N=20 --> 25 Active, not recruiting --> Completed
- ||||| Lemtrada (alemtuzumab) / Sanofi
Enrollment closed: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (clinicaltrials.gov) - Jan 19, 2012
P3, N=1322, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting